The Victorian Heart Hospital and Victorian Heart Institute, operated by Monash Health in partnership with Monash University, have led a groundbreaking first-in-human trial of a gene-editing therapy that could permanently lower cholesterol and triglyceride levels in people with difficult-to-treat lipid disorders.
Monash leads world-first trial of cholesterol-lowering gene-editing therapy
November 10, 2025 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News

